May 5, 2020 / 9:59 PM / a month ago

BRIEF-Scholar Rock Announces Initiation Of Patient Dosing In Phase 1 Proof-Of-Concept Immuno-Oncology Trial Of Srk-181 To Overcome Primary Resistance To Anti-Pd-(L)1 Therapy

May 5 (Reuters) - Scholar Rock Holding Corp:

* SCHOLAR ROCK ANNOUNCES INITIATION OF PATIENT DOSING IN PHASE 1 PROOF-OF-CONCEPT IMMUNO-ONCOLOGY TRIAL OF SRK-181 TO OVERCOME PRIMARY RESISTANCE TO ANTI-PD-(L)1 THERAPY

* SCHOLAR ROCK HOLDING CORP - UPDATE ON DOSE ESCALATION IS EXPECTED IN Q4 OF 2020 FROM SRK-181 TRIAL

* SCHOLAR ROCK HOLDING CORP - CLINICAL RESPONSE AND SAFETY DATA ANTICIPATED IN 2021 FROM SRK-181 TRIAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below